BioSpace News Archive

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced findings from a post hoc analysis of two long-term studies (KINECT™ 3 and KINECT™ 4) of INGREZZA® (valbenazine) capsules evaluating global tardive dyskinesia (TD) improvement and stability of psychiatric symptoms in adults with TD and schizophrenia or schizoaffective disorder.

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases.

Hillstream BioPharma, Inc. today announced the appointment of Kelly Anderson to its Board of Directors and committees, effective as of May 9, 2023.

Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today reported consolidated first-quarter 2023 financial results and provided Company updates.

Telesis Bio Inc. today announced they will be showcasing their benchtop automation solutions for DNA and mRNA synthesis at Protein Engineering Summit (PEGS Boston 2023) which begins today in Boston, Massachusetts.

Acutus Medical, Inc. is pleased to announce its participation in the upcoming Heart Rhythm Society (HRS) Annual Scientific Sessions in New Orleans, LA from May 19-21, 2023.

CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today reported financial results for the first quarter ended March 31, 2023.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor®, an intravenously delivered formulation of ibuprofen, to now include use in infants.

NeuroSense Therapeutics Ltd. today announced the completion of enrollment in PARADIGM, a multinational, randomized, double-blind, placebo-controlled Phase 2b clinical trial of PrimeC in people living with amyotrophic lateral sclerosis (ALS).

Therapeutic Solutions International (TSOI) spin-off Res Nova Bio announced today a collaboration with Cure Stat Rx, a premiere compounding Pharmacy in the manufacture of initiate doses of FloraStilbene™ for a planned 12 patient Phase I/II trial aimed at assessing immunomodulatory activity of the drug candidate in advanced breast cancer patients.